| scholarly article | Q13442814 |
| P356 | DOI | 10.1093/JAC/39.1.5 |
| P698 | PubMed publication ID | 9044021 |
| P50 | author | David A. Barrett | Q41452425 |
| Robin Spiller | Q42693271 | ||
| Nick Shaw | Q42884000 | ||
| Patrick Omonua Erah | Q71593908 | ||
| P2093 | author name string | A F Goddard | |
| P433 | issue | 1 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | clarithromycin | Q118551 |
| metronidazole | Q169569 | ||
| Helicobacter pylori | Q180556 | ||
| amoxicillin | Q201928 | ||
| Helicobacter pylori infectious disease | Q4497153 | ||
| P304 | page(s) | 5-12 | |
| P577 | publication date | 1997-01-01 | |
| P1433 | published in | Journal of Antimicrobial Chemotherapy | Q6294770 |
| P1476 | title | The stability of amoxycillin, clarithromycin and metronidazole in gastric juice: relevance to the treatment of Helicobacter pylori infection | |
| P478 | volume | 39 |
| Q28481230 | A data-driven predictive approach for drug delivery using machine learning techniques |
| Q38268630 | Amoxicillin loaded chitosan-alginate polyelectrolyte complex nanoparticles as mucopenetrating delivery system for h. Pylori |
| Q36172465 | Anti-Helicobacter pylori potential of artemisinin and its derivatives |
| Q35598058 | Appropriate first-line regimens to combat Helicobacter pylori antibiotic resistance: an Asian perspective. |
| Q43682865 | CYP2C19 genotype related effect of omeprazole on intragastric pH and antimicrobial stability |
| Q27005916 | CYP2C19 polymorphism influences Helicobacter pylori eradication |
| Q34663892 | Crosstalk between Helicobacter pylori and gastric epithelial cells is impaired by docosahexaenoic acid |
| Q90260495 | Current and Future Treatment of Helicobacter pylori Infections |
| Q49425208 | Determination of metronidazole in a rat stomach by HPLC for obtaining basic data of the eradication therapy of Helicobacter pylori |
| Q35200053 | Diagnostic methods for Helicobacter pylori detection and eradication |
| Q40697296 | Direct compressible polymethacrylic acid-starch compositions for site-specific drug delivery |
| Q28345560 | Effect of acid secretion blockade by omeprazole on the relative bioavailability of orally administered furazolidone in healthy volunteers |
| Q34444010 | Effect of rabeprazole on the transport and distribution of levofloxacin in rat stomachs |
| Q42371575 | Effective and safe proton pump inhibitor therapy in acid-related diseases - A position paper addressing benefits and potential harms of acid suppression |
| Q35208637 | Effectiveness of ranitidine bismuth citrate and proton pump inhibitor based triple therapies of Helicobacter pylori in Turkey |
| Q43850634 | Effects of CYP2C19 gene polymorphism on cure rates for Helicobacter pylori infection by triple therapy with proton pump inhibitor (omeprazole or rabeprazole), amoxycillin and clarithromycin in Japan |
| Q34706721 | Effects of CYP2C19 loss-of-function variants on the eradication of H. pylori infection in patients treated with proton pump inhibitor-based triple therapy regimens: a meta-analysis of randomized clinical trials |
| Q93052668 | Efficacy of Vonoprazan for Helicobacter pylori Eradication |
| Q37247036 | Esomeprazole- or rabeprazole-based triple therapy eradicated Helicobacter pylori comparably regardless of clarithromycin susceptibility and CYP2C19 genotypes |
| Q41744415 | Gastric diffusion of antibiotics used against Helicobacter pylori |
| Q42607385 | Gastric juice, gastric tissue and blood antibiotic concentrations following omeprazole, amoxicillin and clarithromycin triple therapy |
| Q39471451 | Gastric penetration of amoxicillin in a human Helicobacter pylori-infected xenograft model. |
| Q35102815 | Gastric transitional zones, areas where Helicobacter treatment fails: results of a treatment trial using the Sydney strain mouse model |
| Q36345276 | Gastroduodenal disease, Helicobacter pylori, and genetic polymorphisms |
| Q35108009 | In Vitro Activity of 2-methoxy-1,4-naphthoquinone and Stigmasta-7,22-diene-3β-ol from Impatiens balsamina L. against Multiple Antibiotic-Resistant Helicobacter pylori |
| Q38650879 | In Vitro Activity of Diphenyleneiodonium toward Multidrug-Resistant Helicobacter pylori Strains |
| Q37523457 | In vitro Degradation of Antimicrobials during Use of Broth Microdilution Method Can Increase the Measured Minimal Inhibitory and Minimal Bactericidal Concentrations |
| Q38790570 | Influence of Drug Properties and Formulation on In Vitro Drug Release and Biowaiver Regulation of Oral Extended Release Dosage Forms |
| Q43004789 | Influence of antisecretory drugs on Helicobacter pylori eradication rates. |
| Q37588492 | Insights into the future of gastric acid suppression |
| Q44720785 | Kinetic studies of the degradation of an aminopenicillin antibiotic (amoxicillin trihydrate) in aqueous solution using heat conduction microcalorimetry |
| Q37578697 | Long-term pretreatment with proton pump inhibitor and Helicobacter pylori eradication rates |
| Q44036609 | Measurement of amoxicillin in plasma and gastric samples using high-performance liquid chromatography with fluorimetric detection |
| Q36924777 | Multicenter Study of Antibiotic Resistance Profile of H. pylori and Distribution of CYP2C19 Gene Polymorphism in Rural Population of Chongqing, China |
| Q38862706 | Nanoparticles for oral delivery: Design, evaluation and state-of-the-art |
| Q35128251 | Optimal initiation of Helicobacter pylori eradication in patients with peptic ulcer bleeding |
| Q44371256 | Pharmacogenomics-based tailored versus standard therapeutic regimen for eradication of H. pylori |
| Q33882633 | Pharmacokinetic considerations in the eradication of Helicobacter pylori |
| Q37201668 | Pharmacokinetic- pharmacodynamic analysis of the role of CYP2C19 genotypes in short-term rabeprazole-based triple therapy against Helicobacter pylori |
| Q36334723 | Potent gastric acid inhibition in Helicobacter pylori eradication |
| Q44891811 | Preparation, characterization, and release of amoxicillin from electrospun fibrous wound dressing patches |
| Q55280841 | Proton pump inhibitors: from CYP2C19 pharmacogenetics to precision medicine. |
| Q44249376 | Quantification of clarithromycin, its 14-hydroxy and decladinose metabolites in rat plasma, gastric juice and gastric tissue using high-performance liquid chromatography with electrochemical detection |
| Q36478875 | Review article: the opportunities and benefits of extended acid suppression |
| Q39746768 | Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Single Rising TAK-438 (Vonoprazan) Doses in Healthy Male Japanese/non-Japanese Subjects |
| Q61960641 | The MACH2 study: Role of omeprazole in eradication of Helicobacter pylori with 1-week triple therapies |
| Q42023922 | The effects of varying acidity on Helicobacter pylori growth and the bactericidal efficacy of ampicillin |
| Q43750664 | UV absorption method should not be applied for determining amoxycillin in acidic dissolution test medium |
| Q37282589 | Vonoprazan, a novel potassium-competitive acid blocker, as a component of first-line and second-line triple therapy for Helicobacter pylori eradication: a phase III, randomised, double-blind study |
| Q28072552 | Vonoprazan-based therapy for Helicobacter pylori eradication: experience and clinical evidence |
| Q64051769 | Within-host evolution of Helicobacter pylori shaped by niche-specific adaptation, intragastric migrations and selective sweeps |
Search more.